ECO Animal Health Group receives marketing authorisation from European Medicines Agency

ECO Animal Health Group plc(LON:ECO) has announced that, as anticipated, a marketing authorisation has been received from the European Medicines Agency for the use of Aivlosin® 625 mg/g Water Soluble Granules for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.

The Group had previously announced a positive opinion on 22^nd May 2020 with the marketing authorisation expected within two months.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens. The EU market accounts for approximately 15 per cent of the world’s swine market.

Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Marc Loomes, ECO Animal Health Group CEO, commented: “We are very pleased that this marketing authorisation has been received after only one month and we look forward to offering Aivlosin® for the treatment of Mycoplasma infections in this important market. This further approval underlines the value of Aivlosin® for the safe and highly effective treatment of a range of diseases and infections.”

Share on:

Written by: Giles Arbor

Find more news, interviews, share price & company profile here for:

Latest Company News

CLO income fund Volta Finance delivers 0.4% return in June, NAV at €7.46

In June 2025, Volta Finance achieved a net performance of +0.4%, lifting its cumulative return since August 2024 to +11.2%, with both CLO debt and equity assets posting gains amid easing trade tensions and stable credit markets, and ending the month with a NAV of €7.46 per share.

Thor Energy signs term sheet with Met1 for US project sale

Thor Energy has agreed a term sheet to sell 75% of its US uranium and vanadium subsidiaries to Met1 for a £100,000 exclusivity fee and £1 million in stock, retaining a 25% interest.

Global Opportunities Trust NAV at £110.7 m

As at 30 June 2025, Global Opportunities Trust reported net assets of £110.7 m with equity investments representing 64.6 % of the portfolio. Top holdings include the AVI Japanese Special Situations Fund (12.9 %) and Volunteer Park Capital Fund (7.0 %).

China-focussed UK stock FCSS reports 27% annual share price rise

China’s stimulus drove economic recovery, with stock selection in Hesai Group, LexinFintech and VNET adding value despite underweights in Xiaomi, Xpeng and Tuhu, while over the 12 months to 30 June 2025 the Trust’s NAV rose 28.0% and its share price gained 27.3%, outperforming the reference index’s 23.4%.

UK market a ‘rich pool of investment opportunities’, FSV Factsheet

UK equities delivered modest gains in June, supported by prospects of BoE rate cuts and a more constructive tariff outlook, despite a mid‑month risk‑off following US and Israel strikes on Iranian sites and subsequent relief from a ceasefire.

Fidelity Asian Values significantly outperforms its index over 1 year (LON:FAS)

Over the 12 months to 30 June 2025, the Trust’s NAV rose 4.9%, outperforming its reference index which fell 0.1%, while the share price gained 6.9%. Stock selection was the key driver, with contrarian positions in China and Australia and picks in materials and consumer staples adding value, though an overweight in Indonesian small caps detracted.